Diagnostic test for azoospermia origin
✓ Non-invasive azoospermia biomarkers & Kit development ✓ High sensitivity and specificity (>90%) ✓ Effective azoospermia test in seminal plasma to avoid unnecessary biopsies.
Summary of the technology
✓ Non-invasive azoospermia biomarkers & Kit development
✓ High sensitivity and specificity (>90%)
✓ Effective azoospermia test in seminal plasma to avoid unnecessary biopsies.
Description of the technology
Until now, there is no test with clinical utility to classify the origin of the sperm defects in semen and the spermatogenic reserve of the testis, determinant conditions for an assisted reproductive treatment in those men with no sperm in their ejaculate or azoospermia.
The present invention is focused on the evaluation and assessment of the expression levels of miRNAs contained in exosomes from semen in severe spermatogenic disorders and obstructive azoospermic men. This group of miRNAs could be used as non-invasive biomarkers that contribute in the diagnosis of the origin of azoospermia. Additionally, several miRNAs could be used as noninvasive biomarkers to predict the presence of spermatozoa in secretory azoospermia in order to avoid unnecessary biopsies
This group of miRNAs could be used as noninvasive biomarkers that contribute in the diagnosis of the origin of azoospermia. Those azoospermic cases predicted to be originated from an obstruction of the genitourinary tract have many chances to obtain sperm from the testicular biopsy for the assited reproduction treatment. Additionally, several miRNAs could be used as noninvasive biomarkers to predict the presence of spermatozoa in secretory azoospermia in order to avoid unnecessary biopsies.
Technology Transfer Office
Additional information (attached documents)
Technology Transfer Office from SpainIDIBELL
The Bellvitge Biomedical Research Institute (IDIBELL) is a biomedical research center established in 2004, located in L’Hospitalet de Llobregat, south of Barcelona, Spain. Its stakeholders are Bellvitge University Hospital and Viladecans Hospital of the Catalan Institute of Health, the Catalan Institute of Oncology, University of Barcelona and the City of L’Hospitalet de Llobregat.
IDIBELL comprises more than 1200 researchers integrated in 67 research groups strategically organized in 4 scientific areas: Cancer, Neurosciences, Translational and Regenative Medicine.
The IDIBELL Core Research Facilities include a set of centralized platforms dedicated to developing and providing research resources to assist campus biomedical researchers, such as: biobank, proteomics unit, genomics unit, cytomics unit, C. elegans facility, animal facility, statistical assessment for researchers, Clinical research unit (UICEC) and biomarkers platform. Through these different resources, IDIBELL would like to supply equipment and instrumentation, technical expertise and training to promote innovative, cutting edge research.
IDIBELL has the purpose of connecting academia and industry in order to promote innovative ideas to the market and therefore to society, by supporting professionals along the process.